Published in Medical Devices and Surgical Technology Week, November 28th, 2004
"The recombinant phages used for fabricating phage arrays were initially selected via the use of random peptide phage libraries and breast cancer patient serum antibodies," scientists in Norway explained. "The peptides displayed by the phages retained their ability to be recognized by serum antibodies after immobilization."
"The recombinant phage microarrays were screened against either breast cancer or healthy donor serum antibodies" by L. Cekaite and coauthors at the Norwegian Radium Hospital, who devised a "model-based statistical method"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.